Grupo Insud: a giant with billing of 1.5 billion euros per year

The mAbxience laboratory, which will produce in Argentina the active ingredient to develop the COVID-19 vaccine together with AstraZeneca for the University of Oxford, belongs to the Insud Group, owned by the entrepreneurs Silvia Gold and Hugo Sigman. Although the pharmaceutical area is the leading business, the Group is very diversified and also has investments in agribusiness, forestry, hotels, film production and publishing. It has more than 8,000 employees, is present in 40 countries and will have a turnover of 1.5 billion euros in 2019.

Source: Ámbito